Where Chinese Investors Meet Global Investment News and Opportunities

中國投資者探索環球投資新聞及機遇

CStone Starts Pivotal China Phase II Trial of PD-L1 Candidate

CStone Pharma of Suzhou has begun pivotal Phase II studies of its lead drug, a PD-L1 antibody, in two rare forms of lymphoma: natural killer cell/T-cell lymphoma and classical Hodgkin’s lymphoma. The two trials will test for efficacy and safety. According to CStone, CS1001 is China’s first fully human, full-length, IgG4 based anti-PD-L1 monoclonal antibody, an IO drug that was independently developed by CStone. The first patients have been dosed the two trials.

Source: China Biotoday

Do NOT follow this link or you will be banned from the site!